Day: November 9, 2022

FutureFuel Releases Third Quarter 2022 Results

Written by Customer Service on November 9, 2022. Posted in Earnings Releases And Operating Results.

FutureFuel Third Quarter Net Income of $15.8 Million Reports Net Income of $15.8 Million or $0.36 per Diluted Share, and Adjusted EBITDA of $14.8 Million CLAYTON, Mo., Nov. 09, 2022 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE:FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the third quarter ended September 30, 2022. Third quarter 2022 Financial Highlights (all comparisons are with the third quarter of 2021)Revenues were $118.1 million, up 20% from $98.7 millionAdjusted EBITDA was $14.8 million, up from $11.1 million (see reconciliation table below)Net income was $15.8 million, or $0.36 per diluted share, up 71% from net income of $9.2 million, or $0.21 per diluted share.Nine months 2022 Financial Highlights (all comparisons are with the first nine...

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Written by Customer Service on November 9, 2022. Posted in Earnings Releases And Operating Results.

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR+ recurrent endometrial cancer ONA-XR continues to exhibit favorable safety and tolerability profile Cash and cash equivalents of $39 million as of September 30, 2022, expected to provide runway into Q1 2024 PHILADELPHIA, Nov. 09, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2022. “We are pleased with the continued strengthening...

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

Written by Customer Service on November 9, 2022. Posted in Earnings Releases And Operating Results.

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7 Million ($0.22 per basic and $0.20 per diluted share), which Includes a One Time Charge of $4.1 Million Related to the Acquisition of Ruzurgi® Cash and Short-Term Investments Increased in Q3 2022 by $35.3 Million to $256.1 Million Non-GAAP Net Income for Q3 2022 of $28.6 Million ($0.28 per basic share and $0.26 per diluted share) Company to Host a Conference Call and Webcast on November 10, 2022, at 8:30 AM ET CORAL GABLES, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel...

Sonoco Announces Agreement to Acquire Westrock’s Remaining Interest in Joint Venture: RTS Packaging

Written by Customer Service on November 9, 2022. Posted in Mergers And Acquisitions.

Expands Sustainable Fiber-based Consumer Portfolio HARTSVILLE, S.C., Nov. 09, 2022 (GLOBE NEWSWIRE) — Sonoco Products Company (NYSE: SON) (“Sonoco” or the “Company”), a diversified global packaging leader, today announced it has entered a definitive agreement to purchase the remaining equity interest in RTS Packaging, LLC (“RTS”) from joint venture partner WestRock Company (“WestRock”) and one WestRock paper mill in Chattanooga, Tennessee, for $330 million in cash, subject to customary price adjustments. The valuation is approximately 6.6x adjusted EBITDA without synergies and 5x adjusted EBITDA pro forma for synergies. Sonoco also anticipates that it will be able to achieve $40 million of tax benefits from the transaction. Upon completion of the transaction, Sonoco will own 100% of RTS, formerly operated as a joint venture between...

Cool Company Ltd. – Q3 2022 Business Update

Written by Customer Service on November 9, 2022. Posted in Public Companies.

Cool Company Ltd. will host a Q3 2022 Business Update call and webcast presentation on Wednesday, November 16, 2022, at 10:30A.M. Oslo time. The presentation will be available to download from the Webcasts and Presentations subsection of the Investors section of the company website at www.coolcoltd.com We recommend that participants join the conference call via the listen-only live webcast link provided. Sell-side analysts interested in raising a question during the Q&A session that will immediately follow the presentation should access the event via the conference call by clicking on this link. We recommend connecting 10 minutes prior to call start. Information on how to ask questions will be given at the beginning of the Q&A session. There will be a limit of two questions per participant. a. Listen-only live webcast link Go...

Selectis Health to Present at the Rocky Mountain Microcap Conference X

Written by Customer Service on November 9, 2022. Posted in Public Companies.

Greenwood Village, CO, Nov. 09, 2022 (GLOBE NEWSWIRE) — Selectis Health, Inc. (OTC: GBCS) (“Selectis” or the “Company”), is scheduled to present at Trickle Research’s Rocky Mountain Microcap Conference X, which is being held at TopGolf in Centennial, Colorado on November 10, 2022. Selectis management is scheduled to present on Thursday, November 10th at 1:52 p.m. Mountain time. To receive additional information, request an invitation or schedule a one-on-one meeting with management, please contact Trickle Research or the Company’s investor relations team at selectis@gatewayir.com. About Selectis Health Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and...

Grant of Incentive Subscription Rights in IDEX Biometrics 9 November 2022

Written by Customer Service on November 9, 2022. Posted in Public Companies.

The board of directors of IDEX Biometrics ASA resolved on 9 November 2022 to issue 2,470,000 incentive subscription rights to 15 new and continuing employees and individual contractors in the IDEX Biometrics group. The grant was made under the company’s 2022 incentive subscription rights plan as resolved at the annual general meeting on 12 May 2022. The exercise price of the subscription rights is NOK 1.03 per share. The subscription rights vest by 25% per year over four years and expire on 12 May 2027. Following the grants there are 83,111,447 incentive subscription rights outstanding in IDEX Biometrics. For further information contact:Marianne Bøe, Head of investor relations E-mail: marianne.boe@idexbiometrics.comTel: + 47 9180 0186 About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint...

Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

Written by Customer Service on November 9, 2022. Posted in Public Companies.

YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen2 phase 3 clinical trial will be presented at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting in Louisville, Kentucky on November 12, 2022. ReOpen2 was the second of two phase 3 clinical trials in its ReOpen Program which evaluated XHANCE, also referred to as the Exhalation Delivery System with fluticasone (EDS-FLU), as a potential treatment for chronic sinusitis. ePoster Presentation (P217): Randomized, Controlled Trial of Exhalation Delivery System with Fluticasone For Chronic Rhinosinusitis Without Nasal Polyps, is scheduled for Saturday, November 12, 2022 at 12:05...

EURO Ressources reports earnings for the third quarter and nine months ended September 30, 2022

Written by Customer Service on November 9, 2022. Posted in Earnings Releases And Operating Results.

NEWS RELEASE Paris: EUREURO RESSOURCES REPORTS EARNINGS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022 Paris, France, November 9, 2022: EURO Ressources S.A. (“EURO” or “the Company”) (Paris: EUR) today announced its unaudited statutory interim financial results prepared in accordance with International Financial Reporting Standards (“IFRS”) for the nine months ended September 30, 2022. These unaudited interim financial statements were approved by the Board of Directors on November 9, 2022. All financial amounts are expressed in Euros (“€” or “euros”) unless otherwise specified. Highlights Under IFRS, EURO reported a net profit of €2.9 million (€0.046 per share) and €9.3 million (€0.149 per share) for the three and nine months ended September 30, 2022, respectively, compared to €1.7 million (€0.026 per...

Exodus Reports Third Quarter 2022 Results

Written by Customer Service on November 9, 2022. Posted in Earnings Releases And Operating Results.

OMAHA, Neb., Nov. 09, 2022 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (tZERO: EXOD), (“the Company” or “Exodus”) the leading self-custodial cryptocurrency software platform, today announced its fiscal 2022 results for the third quarter ended September 30, 2022. The Company reported third quarter revenue of $11.0 million, a decrease of 39% year-over-year. Third Quarter 2022 Financial HighlightsIn USD millions, except percentages Q3 2022 Q3 2021 % Change YTD 2022 YTD 2021 % ChangeTotal Revenue $11.0 $18.1 (39%) $39.4 $69.4 (43%)Total Cost of Revenues 6.6 6.9 (4%) 20.9 16.4 27%Operating Expenses 4.5 4.7 (4%) 24.2 16.3 48%(Loss) Income from Operations1 ($0.1 ) $6.5 (102%) ($5.7 ) $36.7 (116%)Operating Margin (1 %) 36 % (15 %) 53 % Net Income (Loss) ($1.3 ) $9.2 ($21.7 ) $31.3 Adjusted...

Day: November 9, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice